CIRC-CARDIOVASC IMAG 润色咨询

Circulation-Cardiovascular Imaging

出版年份:2008 年文章数:1076 投稿命中率: 开通期刊会员,数据随心看

出版周期:Bimonthly 自引率:6.2% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1200217, encodeId=f90b120021e65, content=拒稿以后根据拒稿意见修改,再投同一个杂志有中的机会吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201229/b5a37848c84d49589914e316e825f6a6/20ac2d9c125d4d038df50793d67f65ef.jpg, createdBy=3fd35325265, createdName=17748b9278m, createdTime=Mon Mar 07 13:32:06 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1100709, encodeId=2d441100e09ee, content=什么是推荐reviewer/专家/同行?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1100710, encodeId=6d171100e1025, content=我没有认识的专家,不推荐可以吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920201, encodeId=42589202013d, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:心血管临床方向<br>经验分享:拒稿挺快的,拒稿原因是偏向临床方向,放射学方向的建议转投放射学的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b1a15242236, createdName=147c2ba4m98暂无昵称, createdTime=Wed Jan 27 08:18:45 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544333, encodeId=a82854433391, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481453, encodeId=0c0e4814539d, content=看涨哦,明年会不会再涨?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=513, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:51:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]
    2022-03-07 17748b9278m

    拒稿以后根据拒稿意见修改,再投同一个杂志有中的机会吗

    2

    展开2条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1200217, encodeId=f90b120021e65, content=拒稿以后根据拒稿意见修改,再投同一个杂志有中的机会吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201229/b5a37848c84d49589914e316e825f6a6/20ac2d9c125d4d038df50793d67f65ef.jpg, createdBy=3fd35325265, createdName=17748b9278m, createdTime=Mon Mar 07 13:32:06 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1100709, encodeId=2d441100e09ee, content=什么是推荐reviewer/专家/同行?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1100710, encodeId=6d171100e1025, content=我没有认识的专家,不推荐可以吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920201, encodeId=42589202013d, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:心血管临床方向<br>经验分享:拒稿挺快的,拒稿原因是偏向临床方向,放射学方向的建议转投放射学的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b1a15242236, createdName=147c2ba4m98暂无昵称, createdTime=Wed Jan 27 08:18:45 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544333, encodeId=a82854433391, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481453, encodeId=0c0e4814539d, content=看涨哦,明年会不会再涨?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=513, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:51:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]
    2021-12-28 ms6000000264964247

    什么是推荐reviewer/专家/同行?

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1200217, encodeId=f90b120021e65, content=拒稿以后根据拒稿意见修改,再投同一个杂志有中的机会吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201229/b5a37848c84d49589914e316e825f6a6/20ac2d9c125d4d038df50793d67f65ef.jpg, createdBy=3fd35325265, createdName=17748b9278m, createdTime=Mon Mar 07 13:32:06 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1100709, encodeId=2d441100e09ee, content=什么是推荐reviewer/专家/同行?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1100710, encodeId=6d171100e1025, content=我没有认识的专家,不推荐可以吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920201, encodeId=42589202013d, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:心血管临床方向<br>经验分享:拒稿挺快的,拒稿原因是偏向临床方向,放射学方向的建议转投放射学的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b1a15242236, createdName=147c2ba4m98暂无昵称, createdTime=Wed Jan 27 08:18:45 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544333, encodeId=a82854433391, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481453, encodeId=0c0e4814539d, content=看涨哦,明年会不会再涨?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=513, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:51:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]
    2021-12-27 ms6000000264964247

    我没有认识的专家,不推荐可以吗?

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=1200217, encodeId=f90b120021e65, content=拒稿以后根据拒稿意见修改,再投同一个杂志有中的机会吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201229/b5a37848c84d49589914e316e825f6a6/20ac2d9c125d4d038df50793d67f65ef.jpg, createdBy=3fd35325265, createdName=17748b9278m, createdTime=Mon Mar 07 13:32:06 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1100709, encodeId=2d441100e09ee, content=什么是推荐reviewer/专家/同行?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1100710, encodeId=6d171100e1025, content=我没有认识的专家,不推荐可以吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920201, encodeId=42589202013d, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:心血管临床方向<br>经验分享:拒稿挺快的,拒稿原因是偏向临床方向,放射学方向的建议转投放射学的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b1a15242236, createdName=147c2ba4m98暂无昵称, createdTime=Wed Jan 27 08:18:45 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544333, encodeId=a82854433391, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481453, encodeId=0c0e4814539d, content=看涨哦,明年会不会再涨?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=513, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:51:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]
    2021-01-27 147c2ba4m98暂无昵称

    审稿速度:1.0 | 投稿命中率:25.0
    偏重的研究方向:心血管临床方向
    经验分享:拒稿挺快的,拒稿原因是偏向临床方向,放射学方向的建议转投放射学的杂志

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=1200217, encodeId=f90b120021e65, content=拒稿以后根据拒稿意见修改,再投同一个杂志有中的机会吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201229/b5a37848c84d49589914e316e825f6a6/20ac2d9c125d4d038df50793d67f65ef.jpg, createdBy=3fd35325265, createdName=17748b9278m, createdTime=Mon Mar 07 13:32:06 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1100709, encodeId=2d441100e09ee, content=什么是推荐reviewer/专家/同行?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1100710, encodeId=6d171100e1025, content=我没有认识的专家,不推荐可以吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920201, encodeId=42589202013d, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:心血管临床方向<br>经验分享:拒稿挺快的,拒稿原因是偏向临床方向,放射学方向的建议转投放射学的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b1a15242236, createdName=147c2ba4m98暂无昵称, createdTime=Wed Jan 27 08:18:45 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544333, encodeId=a82854433391, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481453, encodeId=0c0e4814539d, content=看涨哦,明年会不会再涨?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=513, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:51:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]
    2017-07-16 13805560183

    赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦

    2

    展开2条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=1200217, encodeId=f90b120021e65, content=拒稿以后根据拒稿意见修改,再投同一个杂志有中的机会吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201229/b5a37848c84d49589914e316e825f6a6/20ac2d9c125d4d038df50793d67f65ef.jpg, createdBy=3fd35325265, createdName=17748b9278m, createdTime=Mon Mar 07 13:32:06 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1100709, encodeId=2d441100e09ee, content=什么是推荐reviewer/专家/同行?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1100710, encodeId=6d171100e1025, content=我没有认识的专家,不推荐可以吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920201, encodeId=42589202013d, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:心血管临床方向<br>经验分享:拒稿挺快的,拒稿原因是偏向临床方向,放射学方向的建议转投放射学的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b1a15242236, createdName=147c2ba4m98暂无昵称, createdTime=Wed Jan 27 08:18:45 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544333, encodeId=a82854433391, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481453, encodeId=0c0e4814539d, content=看涨哦,明年会不会再涨?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=513, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:51:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]
    2011-06-29 medwu

    看涨哦,明年会不会再涨?

    0

共13条页码: 1/2页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分